DE602005008053D1 - Eine biomoleküle enthaltende suspensionsformulierung von erhöhter stabilität - freisetzbar über ein implantierbares hilfsmittel - Google Patents

Eine biomoleküle enthaltende suspensionsformulierung von erhöhter stabilität - freisetzbar über ein implantierbares hilfsmittel

Info

Publication number
DE602005008053D1
DE602005008053D1 DE602005008053T DE602005008053T DE602005008053D1 DE 602005008053 D1 DE602005008053 D1 DE 602005008053D1 DE 602005008053 T DE602005008053 T DE 602005008053T DE 602005008053 T DE602005008053 T DE 602005008053T DE 602005008053 D1 DE602005008053 D1 DE 602005008053D1
Authority
DE
Germany
Prior art keywords
released
increased stability
suspension formulation
containing biomolecules
stability containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005008053T
Other languages
English (en)
Inventor
Gunjan Junnarkar
Michael A Desjardin
Kui Liu
Zengji Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intarcia Therapeutics Inc
Original Assignee
Intarcia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35451371&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005008053(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intarcia Therapeutics Inc filed Critical Intarcia Therapeutics Inc
Publication of DE602005008053D1 publication Critical patent/DE602005008053D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
DE602005008053T 2004-05-25 2005-05-23 Eine biomoleküle enthaltende suspensionsformulierung von erhöhter stabilität - freisetzbar über ein implantierbares hilfsmittel Active DE602005008053D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57466204P 2004-05-25 2004-05-25
US65022605P 2005-02-03 2005-02-03
PCT/US2005/017914 WO2005115333A2 (en) 2004-05-25 2005-05-23 A biomolecule-containing formulation of increased stability

Publications (1)

Publication Number Publication Date
DE602005008053D1 true DE602005008053D1 (de) 2008-08-21

Family

ID=35451371

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005008053T Active DE602005008053D1 (de) 2004-05-25 2005-05-23 Eine biomoleküle enthaltende suspensionsformulierung von erhöhter stabilität - freisetzbar über ein implantierbares hilfsmittel

Country Status (17)

Country Link
US (2) US20050266087A1 (de)
EP (1) EP1755650B8 (de)
JP (1) JP2008500345A (de)
KR (1) KR20070046791A (de)
AR (1) AR049118A1 (de)
AT (1) ATE400291T1 (de)
AU (1) AU2005247439B2 (de)
BR (1) BRPI0511593A (de)
CA (1) CA2568714A1 (de)
DE (1) DE602005008053D1 (de)
ES (1) ES2309768T3 (de)
IL (1) IL179279A (de)
MX (1) MXPA06013755A (de)
NZ (1) NZ551258A (de)
PE (1) PE20060456A1 (de)
TW (1) TW200611712A (de)
WO (1) WO2005115333A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
DE60315474T2 (de) * 2002-06-17 2008-04-24 Alza Corp., Mountain View Osmotische abgabesysteme mit osmotischen antrieb und verfahren zur herstellung sowohl des osmotischen antriebs als auch des osmotischen abgabesystems
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ES2350689T3 (es) 2002-12-13 2011-01-26 Durect Corporation Sistema de suministro de fármacos oral que comprende materiales vehículo líquidos de alta viscosidad.
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2006521897A (ja) * 2003-03-31 2006-09-28 アルザ・コーポレーション 内部圧力を放散する手段を備える浸透ポンプ
AR043810A1 (es) * 2003-03-31 2005-08-17 Alza Corp Sistema osmotico de administracion y metodo para disminuir los tiempos de llegada al regimen de funcionamiento en los sistemas osmoticos de administracion
PL380763A1 (pl) * 2003-10-31 2007-03-05 Alza Corporation Pompa osmotyczna z samoczynnie mocowanym korkiem membranowym szybkiego uruchamiania
CN1874763A (zh) * 2003-11-06 2006-12-06 阿尔扎公司 与可植入渗透泵一起使用的模块化吸入速率减小器
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
KR101492361B1 (ko) 2004-09-17 2015-02-11 듀렉트 코퍼레이션 바람직하게 ｓａｉｂ와 같은 당 에스테르를 포함하는 지속적인 국소 마취제 조성물
EP2361630A1 (de) * 2005-02-03 2011-08-31 Intarcia Therapeutics, Inc Implantierbares Arzneimittelfreigabesystem Partikel und eine osmotische Pumpe enthaltend
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US7959938B2 (en) 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
CN102274557B (zh) 2006-08-09 2014-12-03 精达制药公司 渗透性递送系统和活塞组件
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
DK2157967T3 (da) 2007-04-23 2013-04-08 Intarcia Therapeutics Inc Suspensionsformuleringer af insulinotropiske peptider og anvendelser deraf
US20080268270A1 (en) * 2007-04-30 2008-10-30 Wenjie Chen High impact polymer interlayers
JP2011506318A (ja) 2007-12-06 2011-03-03 デュレクト コーポレーション 経口医薬製剤
US8343140B2 (en) * 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
MX352189B (es) 2008-09-04 2017-11-10 Amylin Pharmaceuticals Llc Formulaciones de liberación sostenida usando portadores no acuosos.
PT2343982T (pt) 2008-09-17 2017-07-04 Chiasma Inc Composições farmacêuticas e métodos de administração associados
NZ592113A (en) * 2008-10-15 2012-04-27 Intarcia Therapeutics Inc Highly concentrated drug particles, formulations, suspensions and uses thereof
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
WO2011007327A2 (en) 2009-07-16 2011-01-20 Koninklijke Philips Electronics N.V. Suspension for therapeutic use and device for delivering said suspension
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
KR20140015266A (ko) * 2010-11-24 2014-02-06 듀렉트 코퍼레이션 생분해성 약물 전달 조성물
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2014144975A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10238709B2 (en) 2015-02-03 2019-03-26 Chiasma, Inc. Method of treating diseases
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
EP3458084B1 (de) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Für den glucagonrezeptor selektive polypeptide und verfahren zu deren verwendung
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3565580B1 (de) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Kontinuierlicher verabreichung von exenatid und co-verabreichung von acetaminophen, ethinylestradiol oder levonorgestrel
BR112022013784A2 (pt) 2020-01-13 2022-10-11 Durect Corp Sistemas de distribuição de fármacos de liberação prolongada com impurezas reduzidas e métodos relacionados
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
CN117159480B (zh) * 2023-11-01 2024-03-01 江西赛基生物技术有限公司 一种重组人IFN-γ蛋白冻干小球及其制备方法和应用

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797492A (en) * 1972-12-27 1974-03-19 Alza Corp Device for dispensing product with directional guidance member
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4305927A (en) * 1979-02-05 1981-12-15 Alza Corporation Method for the management of intraocular pressure
US4865845A (en) * 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US4874388A (en) * 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) * 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5219572A (en) * 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
GB9027422D0 (en) * 1990-12-18 1991-02-06 Scras Osmotically driven infusion device
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5288214A (en) * 1991-09-30 1994-02-22 Toshio Fukuda Micropump
DE4137649C2 (de) * 1991-11-15 1997-11-20 Gerhard Dingler Bauelement
US5308348A (en) * 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5368588A (en) * 1993-02-26 1994-11-29 Bettinger; David S. Parenteral fluid medication reservoir pump
US5639477A (en) * 1993-06-23 1997-06-17 Alza Corporation Ruminal drug delivery device
US5697975A (en) * 1994-02-09 1997-12-16 The University Of Iowa Research Foundation Human cerebral cortex neural prosthetic for tinnitus
NL9401150A (nl) * 1994-07-12 1996-02-01 Nederland Ptt Werkwijze voor het aan een ontvangzijde aanbieden van een van een zendzijde afkomstig eerste aantal videosignalen, alsmede systeem, alsmede zender, alsmede netwerk, en alsmede ontvanger.
DK0788351T3 (da) * 1994-11-10 2003-05-26 Univ Kentucky Res Found Implanterbar, genopfyldelig anordning til hastighedsreguleret lægemiddeladministration direkte til en indre del af kroppen
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US6132420A (en) * 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6156331A (en) * 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6261584B1 (en) * 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6395292B2 (en) * 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
DE69734168T2 (de) * 1996-02-02 2006-01-19 Alza Corp., Mountain View Implantierbares System mit verzögerter Wirkstofffreisetzung
US5976109A (en) * 1996-04-30 1999-11-02 Medtronic, Inc. Apparatus for drug infusion implanted within a living body
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
DE69705746T2 (de) * 1996-12-20 2001-10-31 Alza Corp Injizierbare depotgelzubereitung und herstellungsverfahren
ZA981610B (en) * 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
MY125849A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
IL136326A0 (en) * 1997-12-08 2001-05-20 Genentech Inc Human interferon-epsilon: a type i interferon
JP4215188B2 (ja) * 1997-12-22 2009-01-28 インターシア セラピューティクス，インコーポレイティド 薬剤供給を調節するデバイスのための速度調節膜
DE69822208T2 (de) * 1997-12-29 2005-04-28 Alza Corp., Mountain View Osmotisches verabreichungssystem mit stöpselrückhaltemechanismus
ES2216340T3 (es) * 1997-12-29 2004-10-16 Alza Corporation Dispositivo implantador para implantes subcutaneos.
CA2316886C (en) * 1997-12-30 2007-09-25 Alza Corporation Beneficial agent delivery system with membrane plug
US6248112B1 (en) * 1998-09-30 2001-06-19 C. R. Bard, Inc. Implant delivery system
WO2000025753A2 (en) * 1998-11-02 2000-05-11 Alza Corporation Controlled delivery of active agents
PT1140014E (pt) * 1998-12-31 2003-07-31 Alza Corp Sistema de distribuicao osmotico que possui embolo com utilizacao eficaz de espaco
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US20030059376A1 (en) * 1999-06-04 2003-03-27 Libbey Miles A. Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US6436091B1 (en) * 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
ES2248156T3 (es) * 1999-12-21 2006-03-16 Alza Corporation Valvula para dispositivos osmoticos.
US6283949B1 (en) * 1999-12-27 2001-09-04 Advanced Cardiovascular Systems, Inc. Refillable implantable drug delivery pump
US20030211974A1 (en) * 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
US6840831B2 (en) * 2000-09-05 2005-01-11 Robert Katz Kickboard
IL155730A0 (en) * 2000-11-03 2003-11-23 Biomedicines Inc Method for short-term and long-term drug dosimetry
AU2002320122B2 (en) * 2001-06-21 2007-07-26 Genentech, Inc. Sustained release formulation
US7163688B2 (en) * 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
EP1572915A4 (de) * 2002-04-11 2011-01-05 Medimmune Vaccines Inc Konservierung von bioaktiven materialien durch sprühtrocknen
DE60315474T2 (de) * 2002-06-17 2008-04-24 Alza Corp., Mountain View Osmotische abgabesysteme mit osmotischen antrieb und verfahren zur herstellung sowohl des osmotischen antriebs als auch des osmotischen abgabesystems
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
DE60317225T2 (de) * 2002-06-26 2008-05-29 Intarcia Therapeutics, Inc., Emeryville Minimal nachgiebiger volumen-effizienter kolben für osmotische medikamentenabgabesysteme
NZ537955A (en) * 2002-07-31 2007-10-26 Alza Corp Injectable depot compositions and uses thereof
KR20050088288A (ko) * 2002-11-06 2005-09-05 알자 코포레이션 제어식 방출 데포 제형
US7014636B2 (en) * 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
US20040224903A1 (en) * 2002-12-19 2004-11-11 Stephen Berry Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2006521897A (ja) * 2003-03-31 2006-09-28 アルザ・コーポレーション 内部圧力を放散する手段を備える浸透ポンプ
CA2520775A1 (en) * 2003-03-31 2004-10-21 Alza Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
AR043810A1 (es) * 2003-03-31 2005-08-17 Alza Corp Sistema osmotico de administracion y metodo para disminuir los tiempos de llegada al regimen de funcionamiento en los sistemas osmoticos de administracion
WO2005032524A2 (en) * 2003-09-30 2005-04-14 Alza Corporation Osmotically driven active agent delivery device providing an ascending release profile
PL380763A1 (pl) * 2003-10-31 2007-03-05 Alza Corporation Pompa osmotyczna z samoczynnie mocowanym korkiem membranowym szybkiego uruchamiania
CN1874763A (zh) * 2003-11-06 2006-12-06 阿尔扎公司 与可植入渗透泵一起使用的模块化吸入速率减小器
US20050118206A1 (en) * 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US20050175701A1 (en) * 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060216242A1 (en) * 2005-02-03 2006-09-28 Rohloff Catherine M Suspending vehicles and pharmaceutical suspensions for drug dosage forms
EP2361630A1 (de) * 2005-02-03 2011-08-31 Intarcia Therapeutics, Inc Implantierbares Arzneimittelfreigabesystem Partikel und eine osmotische Pumpe enthaltend
WO2006083761A2 (en) * 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US7959938B2 (en) * 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
US20070027105A1 (en) * 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
CN102274557B (zh) * 2006-08-09 2014-12-03 精达制药公司 渗透性递送系统和活塞组件
DK2157967T3 (da) * 2007-04-23 2013-04-08 Intarcia Therapeutics Inc Suspensionsformuleringer af insulinotropiske peptider og anvendelser deraf
US8343140B2 (en) * 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents

Also Published As

Publication number Publication date
WO2005115333A3 (en) 2006-05-18
CA2568714A1 (en) 2005-12-08
BRPI0511593A (pt) 2008-01-02
MXPA06013755A (es) 2007-02-08
PE20060456A1 (es) 2006-06-02
IL179279A0 (en) 2007-03-08
US20080112994A1 (en) 2008-05-15
EP1755650B1 (de) 2008-07-09
EP1755650B8 (de) 2008-10-15
ATE400291T1 (de) 2008-07-15
AU2005247439B2 (en) 2010-02-11
ES2309768T3 (es) 2008-12-16
NZ551258A (en) 2009-07-31
IL179279A (en) 2010-06-30
AU2005247439A1 (en) 2005-12-08
AR049118A1 (es) 2006-06-28
TW200611712A (en) 2006-04-16
JP2008500345A (ja) 2008-01-10
EP1755650A2 (de) 2007-02-28
WO2005115333A2 (en) 2005-12-08
KR20070046791A (ko) 2007-05-03
US20050266087A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
DE602005008053D1 (de) Eine biomoleküle enthaltende suspensionsformulierung von erhöhter stabilität - freisetzbar über ein implantierbares hilfsmittel
DE602004024609D1 (de) Korrektur von Ausrichtungsfehlern
DE602005019873D1 (de) Kristalline formen von duloxetin als freie base
DE602005007499D1 (de) Herstellung von 3-hydroxycarbonsäure unter verwendung von nitrilasemutanten
DK1656345T3 (da) Cykliske derivater som modulatorer af chemokinreceptoraktivitet
ATE461188T1 (de) Verstärker von glutamat-rezeptoren
ATE543797T1 (de) Quaternäre alpha-aminocarbonsäureamidderivate als modulatoren von spannungsabhängigen natriumkanälen
ATE504588T1 (de) Stabile salze von olanzapin
DK1490064T3 (da) Substituerede pyridinoner som modulatorer af p38 MAP kinase
DE602005022069D1 (de) Effiziente auswertung von abfragen mittels übersetzung
DE602005008153D1 (de) Kalibrierung von Farbgeräten
DE602004010729D1 (de) Herstellung von verbesserten Silizium-basierten MEMS-Vorrichtungen
DK1745052T3 (da) HIV-intergrase-inhibitorer: cykliske pyrimidinonforbindelser
DE502005006286D1 (de) Verwendung von trisubstituierten benzopyranonen
ATE417837T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
DE602006001938D1 (de) Monohydrochloridsalz von 1-ä3-ä3-(4-chlorphenyl)propoxyüpropylüpiperidin
DE502006004941D1 (de) Von hohlprofilen
DE602004031841D1 (de) Impulsansteuerung von resonanten mems-vorrichtungen
DE502004011575D1 (de) Verwendung von Dioldimerfettsäureestern
ATE384530T1 (de) 4-aminochinolin-3-carbonsäureamid-derivate als pde4-hemmer
NO20070299L (no) Novel heterocyclic compounds
DE602006008937D1 (de) N-amidderivate von 8-azabicycloä3.2.1üoct-3-yl als ccr1-antagonisten
ATE443512T1 (de) Pharmazeutische zusammensetzung von piperazinderivaten
DE602005013066D1 (de) Ein salz von mirtazapin enthaltende pharmazeutische zusammensetzung
DE602004027579D1 (de) Netzwerkbasiertes Piconetz ohne Verwendung eines Piconetz-Koordinators

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: INTARCIA THERAPEUTICS, INC., HAYWARD, CA, US

8364 No opposition during term of opposition